Oral AZD8165 after single oral ascending doses in healthy male subjects

Study identifier:D2890C00001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A phase I, single-center, single-blind, randomized, placebo-controlled study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of oral AZD8165 after single oral ascending doses in healthy male subjects

Medical condition

thrombin inhibition

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD8165

Sex

Male

Actual Enrollment

9

Study type

Interventional

Age

18 Years - 45 Years

Date

Study Start Date: 01 Jun 2010
Primary Completion Date: 01 Aug 2010
Study Completion Date: 01 Aug 2010

Study design

Allocation: N/A
Endpoint Classification: Pharmacokinetics/dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Other

Verification:

Verified 01 Sept 2010 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria